Evidence map›Paper›PMID 37951304›Full record

ArticleIndian heart journal

Ultrathin, biodegradable polymer-coated everolimus-eluting stents for patients undergoing percutaneous coronary intervention: Final three-year results of the PERFORM-EVER registry.

Sridhar Kasturi, Srinivas Polasa, Mohammad Ali Sowdagar, Praveen Kumar, Thejanandan Reddy, Chaitanya Nichenamatla, Shailender Singh, Vijay Kumar Reddy

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Indian heart journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sridhar KasturiSunshine Heart Institute, Hyderabad, Telangana, 500003, India. Electronic address: sridharkasturi@yahoo.com.
Srinivas PolasaChalmeda Anandrao Institute of Medical Sciences, Karimnagar, Telangana, 505001, India. Electronic address: drpolasasrinivas@gmail.com.
Mohammad Ali SowdagarGowri Gopal Hospital, Kurnool, Andhra Pradesh, 518002, India. Electronic address: mdali49@gmail.com.
Praveen KumarGowri Gopal Hospital, Kurnool, Andhra Pradesh, 518002, India. Electronic address: bs_praveen@yahoo.com.
Thejanandan ReddyGowri Gopal Hospital, Kurnool, Andhra Pradesh, 518002, India. Electronic address: tejanandan@gmail.com.
Chaitanya NichenamatlaMedicover Hospital, Kurnool, Andhra Pradesh, 518004, India. Electronic address: chaitunich@gmail.com.
Shailender SinghSunshine Heart Institute, Hyderabad, Telangana, 500003, India. Electronic address: shailendersingh.30@gmail.com.
Vijay Kumar ReddySunshine Heart Institute, Hyderabad, Telangana, 500003, India. Electronic address: svkreddydr@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The registry reports 3-year safety and clinical performance of the ultrathin strut (60 μm) biodegradable polymer-coated Tetrilimus, an everolimus-eluting stent (EES) (Sahajanand Medical Technologies Limited, India), in 'real-world' patients with coronary artery disease. A total of 815 Tetrilimus EES were implanted in 735 lesions in 594 patients. At 3-year follow-up, primary endpoint (target lesion failure, TLF) was reported in 8.6 % patients, including 2.6 % cardiac deaths, 3.5 % myocardial infarction and 2.6 % target lesion revascularization. At three-year, no cases of definite stent thrombosis were reported. The final three-year results of PERFORM-EVER registry endorse the continuous safety and effectiveness Tetrilimus EES.

Indexed as

Drug-Eluting StentsPercutaneous Coronary InterventionAbsorbable ImplantsEverolimusHumansPolymersProsthesis DesignRegistriesSirolimusStentsTreatment OutcomeEverolimusPolymersSirolimusCoronary artery diseaseDrug-eluting stentsPercutaneous coronary intervention

Identifiers

PMID37951304
PMCPMC10774589

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.